Compare Dollar General Corp. (DG) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs McKesson Corporation — how do they compare? Dollar General Corp. trades at $124.27 (market cap $26.95B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 3.9× Dollar General Corp.'s market cap, and Dollar General Corp. pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and McKesson Corporation for 74 Days on average.
| DG | MCK | |
|---|---|---|
Market Cap | $26.95B | $106.14B |
Volume | 1,654,929 | 794,405 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $995.69 |
52-Week Low | $95.94 | $725.17 |
Typical Hold Time | 59 Days | 74 Days |
Enterprise Value | $41.13B | $112.67B |
Dividend Yield | 1.93% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 0.82% on the day, with a neutral technical signal and bearish moving average trend. The stock shows strong valuation metrics with a P/E of 15.86 and P/S of 0.62, while recent earnings have consistently beaten estimates. Revenue growth is steady, reaching $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart.
The outlook is cautiously optimistic, supported by analyst consensus price target of $137.27 (10.5% upside) and a 55.77% buy rating. Key opportunities include margin recovery initiatives and digital growth, while risks involve competitive pressures and consumer spending volatility. The stock presents a value opportunity with upside potential if execution improves.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
